[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2018157832A1 - Kit de surveillance du cancer gastrique et procédé d'utilisation associé - Google Patents

Kit de surveillance du cancer gastrique et procédé d'utilisation associé Download PDF

Info

Publication number
WO2018157832A1
WO2018157832A1 PCT/CN2018/077714 CN2018077714W WO2018157832A1 WO 2018157832 A1 WO2018157832 A1 WO 2018157832A1 CN 2018077714 W CN2018077714 W CN 2018077714W WO 2018157832 A1 WO2018157832 A1 WO 2018157832A1
Authority
WO
WIPO (PCT)
Prior art keywords
gastric cancer
reagent
monitoring kit
cancer monitoring
reaction
Prior art date
Application number
PCT/CN2018/077714
Other languages
English (en)
Chinese (zh)
Inventor
陈翠英
Original Assignee
江苏先思达生物科技有限公司
先思达（南京）生物科技有限公司
常州吉泰生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏先思达生物科技有限公司, 先思达（南京）生物科技有限公司, 常州吉泰生物科技有限公司 filed Critical 江苏先思达生物科技有限公司
Publication of WO2018157832A1 publication Critical patent/WO2018157832A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Definitions

  • the invention belongs to the technical field of biomedicine, and particularly relates to a gastric cancer monitoring kit and a using method thereof.
  • Gastric cancer is a malignant tumor disease that threatens the health of human beings around the world. Although the incidence of gastric cancer has generally declined in recent decades, the incidence rate in all cancers still ranks second, with mortality accounting for the first place. The incidence of gastric cancer in men worldwide is second only to lung, prostate and colorectal cancer, accounting for the fourth place; women have the fifth highest rate of gastric cancer, after breast cancer, cervical cancer, colorectal cancer and lung cancer. . According to statistics, there are about 380,000 new cases of gastric cancer in China each year, and 160,000 deaths. From the age of onset, there is a trend of younger age, and the incidence of gastric cancer in young people is gradually increasing. Different from gender, male patients are more than female, and young patients are mostly female patients.
  • the status quo of gastric cancer patients in China is characterized by “three highs and three lows”, namely, high incidence rate, metastasis rate and mortality rate; early diagnosis rate, radical resection rate, and 5-year survival rate are low.
  • the incidence and mortality of gastric cancer showed a decreasing trend from 2000 to 2011, the incidence of gastric cancer in men still accounted for the second place in all cancers, and the mortality rate was the third.
  • the incidence of gastric cancer in women is only the fifth in all cancers, the mortality rate is the second.
  • the pathological type of gastric cancer is based on histomorphological structure and cell biological characteristics. Different types of gastric cancer have different morphological structures and biological behaviors, and the epidemiology and molecular mechanism are different, so that the existing gastric cancer pathological scores There are many types of systems. With the continuous development of science and technology, the understanding of gastric cancer has gradually deepened. From the initial histomorphology study of gastric cancer to the current study of gastric cancer at the molecular level, the classification of gastric cancer has also changed with the change from general form to tissue. Types are based on environmental, genetic and epidemiological typing, to genotyping. At present, the most important and most common are Lauren classification and WHO classification.
  • the current diagnostic kit for gastric cancer detects some common tumor markers with low sensitivity and accuracy.
  • the main reason is that the single detection of selected tumor markers often has great limitations and it is difficult to meet the requirements of rapid diagnosis.
  • a glycoprotein molecule consists of a polypeptide chain and a sugar moiety. Any change in serum glycoproteins can reflect physiological changes in the body. Recent studies in glycomics have also shown that changes in oligosaccharide chains are closely related to the occurrence and development of various tumors (References: Liu, XE, Desmyter, L, Gao, CF, Laroy, W, Dewaele, S, Vanhooren, V, Wang, L, Zhuang, H, Callewaert, N, Libert, C, Contreras, R, Chen, CN-Glycomic changes in hepatocell ⁇ Lar carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology, 46, 1426-1435, 2007.).
  • the object of the present invention is to solve the uncertainty of monitoring of gastric cancer by the existing detection method, and to provide a gastric cancer monitoring kit and a method for using the same, which are capable of detecting carbohydrates (oligosaccharides) linked by glycosidic bonds of blood glycoproteins
  • the change in content is used to assess the progression of gastric cancer and the recurrence of tumors.
  • a gastric cancer monitoring kit consisting of the following reagents:
  • Reagent A a solution of 10% by mass of ammonium bicarbonate in a solution of 5% by mass of SDS;
  • Reagent B a mass concentration of 10% NP40 is prepared by adding not less than 2.4 units/ ⁇ L of a glycoside exonuclease
  • Reagent C a mixture of 1.2 M citric acid in an equal volume of 20 mM APTS and 2 M organic reducing agent in DMSO;
  • Reagent D 0.5 ⁇ L of NH 4 AC at a concentration of 100 mM, pH 5.6, not less than 0.2 ⁇ L of sialidase, 2.50 ⁇ L of hydrogen peroxide.
  • organic reducing agent is NaCNBH 3 .
  • the volume of the reagent A may be 3 ⁇ L
  • the volume of the reagent B may be 3 ⁇ L
  • the volume of the reagent C may be 4 ⁇ L
  • the volume of the reagent D may be 3 ⁇ L.
  • the method for using the above gastric cancer monitoring kit includes the following steps:
  • Step 1 adding 3 ⁇ L of reagent A to the diluted 3 ⁇ L serum, performing denaturation reaction, adding 3 ⁇ L of reagent B, reacting at 37 ° C for 4 hours, and then drying to obtain a sample;
  • Step 2 adding 4 ⁇ L of reagent C to the obtained sample, performing fluorescent labeling, and then adding 150 ⁇ L of water to terminate the labeling reaction to obtain a fluorescently labeled sample;
  • Step 3 adding 3 ⁇ L of reagent D to 5 ⁇ L of the fluorescently labeled sample, performing a terminal sialic acid reaction, and adding 100 ⁇ L of water to terminate the labeling reaction to obtain a sample of the terminal sialic acid reaction;
  • step 4 8 ⁇ L of the end-sialic acid-reacted sample was taken, and the oligosaccharide chain was separated by an ABI sequencer to obtain a map.
  • condition of the step 1 denaturation reaction is heating not lower than 95 °C.
  • condition of fluorescent labeling in step 2 is 60-70 ° C heating.
  • condition of the terminal sialic acid reaction in the step 3 is heating not higher than 45 °C.
  • the above gastric cancer monitoring kit can be used for detecting blood or human body fluid containing oligosaccharide chain components.
  • the gastric cancer monitoring kit of the present invention is based on the detection of a fingerprint of oligosaccharide chains in blood glycoproteins as a diagnostic index for evaluating gastric cancer patients to diagnose tumor staging of gastric cancer, and the detection method can allow many gastric cancer patients to receive routine, Non-invasive testing helps doctors detect stomach cancer and monitor disease progression in a timely manner.
  • Example 1 is a schematic flow chart of the analysis of the N-oligosaccharide chain fingerprinting technique using serum in Example 1;
  • Example 2 is a G-Test map of human serum used in Example 1;
  • Figure 3 is a serum G-Test spectrum of the healthy control group in Example 1;
  • Example 4 is a serum G-Test chart of a lung cancer patient in Example 1.
  • the study found that there is a significant correlation between the change in glycoside-linked carbohydrate content of blood glycoproteins and the histology of gastric cancer patients. Further, the clinical monitoring method for assessing gastric cancer can effectively screen and regularly evaluate the progress of gastric cancer and the recurrence of tumor after treatment.
  • serum oligosaccharide chain fingerprinting technology (G-Test method for short) is used as a diagnostic index for gastric cancer patients.
  • the main steps of the method are: releasing and fluorescently labeling the oligosaccharide chain of the glycoprotein in the serum or plasma sample; separating the content or fingerprint of the fluorescently labeled oligosaccharide chain in the measurement sample (referred to as G-Test map); analyzing and comparing the oligosaccharide Fingerprint map, get the test index parameters, the specific process is shown in Figure 1.
  • This method can enable many patients with gastric cancer to receive routine, non-invasive testing, help doctors to detect gastric cancer, and timely monitor the occurrence of disease and the progress of the disease.
  • the composition for monitoring the risk of developing gastric cancer or gastric cancer is selected from the group consisting of oligosaccharide chains: NA3F, NA2F, NA2FB, NGA2F, NGA2FB, and NA3.
  • the ratio of (NA3+NA2FB)/NA3F was used to diagnose gastric cancer detection.
  • the G-Test spectrum of human serum probably shows nearly 10 N-oligosaccharide chain peaks. Different oligosaccharide chains exhibit different mobility due to different molecular sizes, that is, they are expressed in G-Test.
  • the different peaks on the map represent different oligosaccharide chains; the relative concentration of oligosaccharide chains is expressed in the measured peak height.
  • NGA2F galactose-deficient two antennas containing core fucose ( ⁇ 1,6Fuc);
  • NGA2FB galactose-deficient core fucose modified with halved acetylglucosamine (GlcNAc) ( ⁇ 1, 6Fuc) two antennas;
  • NG1A2F galactose single deletion core fucose ( ⁇ 1,6Fuc) two antennas (single agalacto, core- ⁇ -1,6-fucosylated biantennary); NA2, two antennas (bigalacto, biantennary NA2F, core fucose ( ⁇ 1,6Fuc) two antennas;
  • NA2FB core fucose ( ⁇ 1,6Fuc) antenna with halved acetylglucosamine (GlcNAc) modification;
  • the invention provides a gastric cancer monitoring kit consisting of the following reagents:
  • Reagent A denaturation buffer: 10 mM ammonium bicarbonate SDS;
  • Reagent B (glycosidase reaction buffer): final concentration of exoglycosidase 2.4 units / ⁇ L at 10% NP40;
  • Reagent C (APTS Labeling Buffer): Mix an equal volume of 20 mM APTS (dissolved in 1.2 M citric acid) and 2 M organic reducing agent (dissolved in DMSO);
  • Reagent D sialidase reaction solution: 0.5 ⁇ L of 100 mM NH 4 AC, pH 5.6; 0.2 ⁇ L of sialidase, 2.50 ⁇ L of hydrogen peroxide.
  • the organic reducing agent is preferably NaCNBH 3 .
  • a total of 49 patients with gastric cancer were collected from the serum of this patient.
  • the serum was collected from Zhenjiang First People's Hospital.
  • the serum of 57 healthy controls was from Zhenjiang First People's Hospital.
  • HAV human immunodeficiency virus
  • the equipment is mainly an ABI sequencer (Applied Biosystems) and a capillary electrophoresis system with the same principle of action.
  • the reagent mainly contains reagent A (denaturation buffer): 10 mM ammonium bicarbonate 5% SDS; reagent B (PNGaseF reaction buffer): final concentration of exoglycosidase 2.4 units / ⁇ L at 10% NP40; reagent C (APTS label buffer) Liquid): Mix equal volumes of 20 mM APTS (dissolved in 1.2 M citric acid) and 2 M NaCNBH 3 (dissolved in DMSO); Reagent D (sialidase reaction solution): 0.5 ⁇ L 100 mM NH 4 AC; 0.2 ⁇ L sialidase, 2.50 ⁇ L of hydrogen peroxide.
  • reagent A denaturation buffer
  • reagent B PNGaseF reaction buffer
  • APTS label buffer APTS label buffer
  • the G-Test Atlas analysis procedure consists of four steps:
  • Step 1 Prepare a free oligosaccharide chain with a specific N-glycosidic bond hydrolase: add 3 ⁇ L of reagent A to 3 ⁇ L of diluted serum, and denature at 95 ° C for 5 minutes; then equal volume (3 ⁇ L) of reagent B , reacted at 37 ° C for 4 hours and then dried;
  • Step 2 fluorescently labeling the free oligosaccharide chain: adding 4 ⁇ L of reagent C to the liquid of step 1, heating at 65 ° C for 2 hours for fluorescent labeling, and then adding 150 ⁇ L of water to terminate the labeling reaction;
  • Step 3 remove the terminal sialic acid: take 5 ⁇ L of the fluorescently labeled liquid of step 2, then add 3 ⁇ L of reagent D, heat at 45 ° C for 3 hours to carry out the terminal sialic acid reaction, and then add 100 ⁇ L of water to terminate the labeling reaction;
  • Step 4 Separation and analysis of the fluorescently labeled N-oligosaccharide chain: 8 ⁇ L of the end-to-sialic acid reaction liquid obtained in the step 3 was taken, and the N-oligosaccharide chain fragment was separated by an ABI 3500dx sequencer to obtain a G-Test spectrum.
  • the G-Test map of human serum represents different N-oligosaccharide chain peaks, showing different mobility due to different molecular sizes, ie different peaks on the G-Test map represent different oligosaccharide chains.
  • the relative concentration of the oligosaccharide chain is expressed in the measured peak height. As shown in Fig. 3 and Fig.
  • NA2FB of gastric cancer group and normal control group with two oligoacetylglucosamine (GlcNAc) modified core fucose ( ⁇ 1,6Fuc) antennas; NA3, three antennas; NA3F
  • the three antennas modified by branched fucose ( ⁇ 1,3/1,2Fuc) have a significant gap, the change of N-glycosidically linked carbohydrate (N-oligosaccharide) content of blood glycoprotein and the histology of gastric cancer patients There is a significant correlation between them.
  • the setting of (NA3+NA2FB)/NA3F was greater than 4 for the normal group, and 51 of the normal group were satisfactory. It is 89.5%.
  • the threshold of (NA3+NA2FB)/NA3F was less than 2, it was the gastric cancer group, and in the gastric cancer group, 43 cases met the requirement, and the accuracy was 87.8%.
  • the results indicate that there is a significant correlation between the change in the N-glycosidically linked carbohydrate (N-oligosaccharide) content of the blood glycoprotein and the histology of the gastric cancer patient.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un kit de surveillance du cancer gastrique et son procédé d'utilisation, le kit comprenant : un réactif A, qui est préparé par ajout de 5 % de SDS à une solution de bicarbonate d'ammonium ayant une concentration de 10 mM ; un réactif B, qui est préparé en ajoutant pas moins de 2,4 unité/µL d'exoglycosidase à NP40 ayant une concentration de 10 % ; un réactif C, qui est un mélange liquide composé, en volume égal, une solution de 20 mM d'APTS dissous dans 1,2 M d'acide citrique et d'une solution de 2M d'un agent réducteur organique dissous dans du DMSO ; et un réactif D, qui comprend 0,5 µL de NH4AC ayant une concentration de 100 mM et un pH de 5,6, 0,2 µL de sialidase, et 2,50 µL de peroxyde d'hydrogène. Le kit, sur la base d'un spectre d'empreintes digitales pour détecter des chaînes oligosaccharidiques dans une glycoprotéine sanguine servant d'index diagnostique, évalue un patient atteint d'un cancer gastrique, de telle sorte qu'un stade tumoral du cancer gastrique est diagnostiqué.
PCT/CN2018/077714 2017-03-02 2018-03-01 Kit de surveillance du cancer gastrique et procédé d'utilisation associé WO2018157832A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710120659.4A CN106950380B (zh) 2017-03-02 2017-03-02 一种胃癌监测试剂盒及其使用方法
CN201710120659.4 2017-03-02

Publications (1)

Publication Number Publication Date
WO2018157832A1 true WO2018157832A1 (fr) 2018-09-07

Family

ID=59467136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/077714 WO2018157832A1 (fr) 2017-03-02 2018-03-01 Kit de surveillance du cancer gastrique et procédé d'utilisation associé

Country Status (2)

Country Link
CN (1) CN106950380B (fr)
WO (1) WO2018157832A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106950380B (zh) * 2017-03-02 2019-01-11 江苏先思达生物科技有限公司 一种胃癌监测试剂盒及其使用方法
CN106950379B (zh) * 2017-03-02 2019-01-22 江苏先思达生物科技有限公司 一种肺癌监测试剂盒及其使用方法
CN109100507A (zh) * 2017-06-20 2018-12-28 江苏先思达生物科技有限公司 慢性肝炎肝损伤的血清糖蛋白n-糖组图谱模型的建立方法
CN114032282A (zh) * 2021-09-15 2022-02-11 陈翠英 一种前列腺癌检测试剂及其在前列腺癌检测中的应用
CN114032283A (zh) * 2021-09-15 2022-02-11 陈翠英 一种肠癌检测试剂及其在肠癌检测中的应用
CN114058673A (zh) * 2021-09-15 2022-02-18 江苏先思达生物科技有限公司 一种脂肪肝检测试剂及其在脂肪肝检测中的应用
CN114032284A (zh) * 2021-09-15 2022-02-11 陈翠英 一种食管癌检测试剂及其在食管癌检测中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101576495A (zh) * 2009-06-09 2009-11-11 中国人民解放军第二军医大学 一种检测血清N糖log(P9/P4)的方法、检测系统及其应用
CN101779128A (zh) * 2007-06-14 2010-07-14 弗拉芒区生物技术研究所 早期肝癌检测的诊断测试
US20110092374A1 (en) * 2009-10-16 2011-04-21 Vib, Vzw Methods for producing substantially homogeneous hybrid or complex n-glycans in methylotrophic yeasts
CN102565318A (zh) * 2012-01-11 2012-07-11 陈翠英 一种肝癌监测、分期以及预后风险评估的试剂及其方法
CN102707062A (zh) * 2011-03-27 2012-10-03 上海交通大学附属第一人民医院 检测慢性乙肝肝纤维化血清n-糖组峰标记的方法及其用途
CN104807998A (zh) * 2015-05-12 2015-07-29 先思达（南京）生物科技有限公司 一种早期肝癌诊断试剂盒及其使用方法
CN105372214A (zh) * 2014-08-18 2016-03-02 中国科学院上海有机化学研究所 一种鉴定新红细胞生成刺激蛋白的n-连接寡糖结构的方法
CN106950380A (zh) * 2017-03-02 2017-07-14 先思达（南京）生物科技有限公司 一种胃癌监测试剂盒及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101451975B (zh) * 2008-12-29 2012-01-25 浙江大学 一种检测胃癌预后与分期血清蛋白质的方法
US20150017669A1 (en) * 2013-07-10 2015-01-15 Hudson Surface Technology, Inc. Process and its application for improving reproducibility in maldi-tof glycan profiling of human serum: experimental procedure and application to the screening for ovarian tumors
WO2016036705A1 (fr) * 2014-09-03 2016-03-10 Musc Foundation For Research Development Panneaux de glycanes constituant des biomarqueurs de tissus de tumeur spécifiques
CN105699473B (zh) * 2016-03-23 2018-11-06 深圳市老年医学研究所 胃癌唾液蛋白指纹图谱分子诊断模型建立方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101779128A (zh) * 2007-06-14 2010-07-14 弗拉芒区生物技术研究所 早期肝癌检测的诊断测试
CN101576495A (zh) * 2009-06-09 2009-11-11 中国人民解放军第二军医大学 一种检测血清N糖log(P9/P4)的方法、检测系统及其应用
US20110092374A1 (en) * 2009-10-16 2011-04-21 Vib, Vzw Methods for producing substantially homogeneous hybrid or complex n-glycans in methylotrophic yeasts
CN102707062A (zh) * 2011-03-27 2012-10-03 上海交通大学附属第一人民医院 检测慢性乙肝肝纤维化血清n-糖组峰标记的方法及其用途
CN102565318A (zh) * 2012-01-11 2012-07-11 陈翠英 一种肝癌监测、分期以及预后风险评估的试剂及其方法
CN105372214A (zh) * 2014-08-18 2016-03-02 中国科学院上海有机化学研究所 一种鉴定新红细胞生成刺激蛋白的n-连接寡糖结构的方法
CN104807998A (zh) * 2015-05-12 2015-07-29 先思达（南京）生物科技有限公司 一种早期肝癌诊断试剂盒及其使用方法
CN106950380A (zh) * 2017-03-02 2017-07-14 先思达（南京）生物科技有限公司 一种胃癌监测试剂盒及其使用方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CAUEWAERT, N. ET AL.: "Noninvasive Diagnosis of Liver Cirrhosis Using DNA Sequencer-Based Total Serum Protein Glycomics", NATURE MEDICINE, vol. 10, no. 4, 7 March 2004 (2004-03-07), pages 429 - 434, XP055538395 *
CAUEWAERT, N. ET AL.: "Ultrasensitive Profiling and Sequencing of N-Linked Oligosaccharides Using Standard DNA-Sequencing Equipment", GLYCOBIOLOGY, vol. 11, no. 4, April 2001 (2001-04-01), pages 275 - 281, XP055538397 *
LIU, LONG ET AL.: "The Identification and Characterization of Novel N-Glycan-based Biomarkers in Gastric Cancer", PLOS ONE, vol. 8, no. 10, 17 October 2013 (2013-10-17), pages e77821, XP055538393 *
QIN, LIPING: "Correlation Between the Sera N-Glycome Characteristics and the TCM Syndromes in Gastric Cancer", MEDICINE & PUBLIC HEALTH, CHINA DOCTORAL DISSERTATIONS FULL-TEXT DATABASE, 15 April 2014 (2014-04-15), pages 19 - 29 *
WEIXING ET AL.: "A Relevant Research on Changes in Characteristics of N-Glycan in Gastric Cancer and Its Relationship with TCM Syndromes", CHINESE JOURNAL OF INFORMATION ON TRADITIONAL CHINESE MEDICINE, vol. 2014, no. 9, September 2014 (2014-09-01), pages 36 - 39,40, ISSN: 1005-5304 *
XU, XINYUN ET AL.: "Establishment and Evaluation of New N-Glycan Biomarkers for Diagnosis of Gastric Cancer", CURRENT IMMUNOLOGY, vol. 2013, no. 3, May 2013 (2013-05-01), pages 213 - 218, ISSN: 1001-2478 *
ZHAO, YUNPENG ET AL.: "Decreased Core-Fucosylation Contributes to Malignancy in Gastric Cancer", PLOS ONE, vol. 9, no. 4, 14 April 2014 (2014-04-14), pages e94536, XP055538385 *

Also Published As

Publication number Publication date
CN106950380B (zh) 2019-01-11
CN106950380A (zh) 2017-07-14

Similar Documents

Publication Publication Date Title
WO2018157832A1 (fr) Kit de surveillance du cancer gastrique et procédé d'utilisation associé
CN102565318B (zh) 一种肝癌监测、分期以及预后风险评估的试剂及其方法
WO2018157831A1 (fr) Kit de surveillance du cancer du poumon et sa méthode d'application
CN104004840B (zh) 用于早期筛查与诊断前列腺癌的试剂盒
WO2023040909A1 (fr) Réactif de détection de carcinome oesophagien et son application dans la détection de carcinome oesophagien
CN114032283A (zh) 一种肠癌检测试剂及其在肠癌检测中的应用
CN114032282A (zh) 一种前列腺癌检测试剂及其在前列腺癌检测中的应用
WO2023040908A1 (fr) Réactif de détection de la stéatose hépatique et son utilisation dans la détection de la stéatose hépatique
WO2024183386A1 (fr) Réactif de détection à base de chaîne d'oligosaccharide pour détecter un cancer de la prostate, procédé de préparation et utilisation
WO2024183385A1 (fr) Réactif de détection à base de chaîne d'oligosaccharides pour détecter un cancer intestinal, procédé de préparation, et utilisation
CN116298285A (zh) 一种基于寡糖链检测乳腺癌的检测试剂、制备方法及应用
CN116183921A (zh) 一种基于寡糖链检测胰腺癌的检测试剂、制备方法及应用
CN107247148B (zh) Gp73的新用途及一种基于其的肝组织炎症活动度检测试剂盒
CN109735612A (zh) 川崎病冠状动脉瘤并发症的生物分子标志物及其试剂盒
CN115774109A (zh) 一种基于寡糖链检测胃癌的检测试剂、制备方法及应用
CN114136932A (zh) 一种子宫内膜样腺癌检测试剂及其在子宫内膜样腺癌检测中的应用
WO2020013097A1 (fr) Chaîne de sucre spécifique du cancer de la prostate et procédé de test l'utilisant
CN112180093A (zh) 危重病死亡率诊断性生物标志物tenascin-c及其应用
CN118471335B (zh) 用于诊断宫颈癌淋巴转移的设备、方法、系统及其应用
CN111876483B (zh) Lypd1在肝细胞癌诊断、治疗、预后和预测复发中的应用
CN115902239A (zh) 一种基于寡糖链检测肺癌的检测试剂、制备方法及应用
CN115980359A (zh) 一种基于寡糖链检测乙肝肝癌的检测试剂、制备方法及应用
Rashed et al. Assessment of Liver Fibrosis Using Real Time Elastography and FIB 4 Score in Comparison to Liver Biopsy in Chronic HCV Egyptian Patients
Toutem et al. A Comparitive Study of Serum Pro-Calcitonin (S-Pct) & C-Reactive Protein (CRP) in Patients with Sepsis.
Li et al. The value of HIFI model based on cell-free DNA genomic features in early diagnosis and prediction of hepatocellular carcinoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18761035

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18761035

Country of ref document: EP

Kind code of ref document: A1